157 related articles for article (PubMed ID: 35147302)
1. Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD.
Šmíd V; Dvořák K; Šedivý P; Kosek V; Leníček M; Dezortová M; Hajšlová J; Hájek M; Vítek L; Bechyňská K; Brůha R
Hepatol Commun; 2022 Jun; 6(6):1336-1349. PubMed ID: 35147302
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials.
Chen LH; Wang YF; Xu QH; Chen SS
Clin Nutr; 2018 Apr; 37(2):516-521. PubMed ID: 28040302
[TBL] [Abstract][Full Text] [Related]
4. Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight.
Okada LSDRR; Oliveira CP; Stefano JT; Nogueira MA; Silva IDCGD; Cordeiro FB; Alves VAF; Torrinhas RS; Carrilho FJ; Puri P; Waitzberg DL
Clin Nutr; 2018 Oct; 37(5):1474-1484. PubMed ID: 29249532
[TBL] [Abstract][Full Text] [Related]
5. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease.
Di Minno MN; Russolillo A; Lupoli R; Ambrosino P; Di Minno A; Tarantino G
World J Gastroenterol; 2012 Nov; 18(41):5839-47. PubMed ID: 23139599
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids.
de Castro GS; Calder PC
Clin Nutr; 2018 Feb; 37(1):37-55. PubMed ID: 28139281
[TBL] [Abstract][Full Text] [Related]
7. Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials.
Yan JH; Guan BJ; Gao HY; Peng XE
Medicine (Baltimore); 2018 Sep; 97(37):e12271. PubMed ID: 30212963
[TBL] [Abstract][Full Text] [Related]
8. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.
Nogueira MA; Oliveira CP; Ferreira Alves VA; Stefano JT; Rodrigues LS; Torrinhas RS; Cogliati B; Barbeiro H; Carrilho FJ; Waitzberg DL
Clin Nutr; 2016 Jun; 35(3):578-86. PubMed ID: 26047766
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
Kelley NS
Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
[TBL] [Abstract][Full Text] [Related]
10. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids.
Spahis S; Alvarez F; Ahmed N; Dubois J; Jalbout R; Paganelli M; Grzywacz K; Delvin E; Peretti N; Levy E
J Nutr Biochem; 2018 Aug; 58():28-36. PubMed ID: 29864682
[TBL] [Abstract][Full Text] [Related]
11. Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial.
Cansanção K; Citelli M; Carvalho Leite N; López de Las Hazas MC; Dávalos A; Tavares do Carmo MDG; Peres WAF
Nutrients; 2020 Nov; 12(11):. PubMed ID: 33147705
[TBL] [Abstract][Full Text] [Related]
12. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
[TBL] [Abstract][Full Text] [Related]
13. Can omega-3 fatty acids be beneficial in pediatric NAFLD? A systematic review and meta-analysis.
Dionysopoulos G; Kalopitas G; Vadarlis A; Bakaloudi DR; Gkiourtzis N; Karanika E; Tsekitsidi E; Chourdakis M
Crit Rev Food Sci Nutr; 2023; 63(27):8545-8553. PubMed ID: 35400251
[TBL] [Abstract][Full Text] [Related]
14. [A Future Perspective on the Involvement of n-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis].
Nakamoto K; Obata T; Hirasawa A; Kim KI; Kim SR; Tokuyama S
Yakugaku Zasshi; 2016; 136(4):583-9. PubMed ID: 27040343
[TBL] [Abstract][Full Text] [Related]
15. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
Bhatia L; Scorletti E; Curzen N; Clough GF; Calder PC; Byrne CD
Atherosclerosis; 2016 Mar; 246():13-20. PubMed ID: 26748347
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Parker HM; Johnson NA; Burdon CA; Cohn JS; O'Connor HT; George J
J Hepatol; 2012 Apr; 56(4):944-51. PubMed ID: 22023985
[TBL] [Abstract][Full Text] [Related]
17. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.
Zhu FS; Liu S; Chen XM; Huang ZG; Zhang DW
World J Gastroenterol; 2008 Nov; 14(41):6395-400. PubMed ID: 19009658
[TBL] [Abstract][Full Text] [Related]
18. Associations of serum n-3 and n-6 polyunsaturated fatty acids with prevalence and incidence of nonalcoholic fatty liver disease.
Mäkelä TNK; Tuomainen TP; Hantunen S; Virtanen JK
Am J Clin Nutr; 2022 Sep; 116(3):759-770. PubMed ID: 35648467
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease and Omega-3 Fatty Acids: Mechanisms and Clinical Use.
Spooner MH; Jump DB
Annu Rev Nutr; 2023 Aug; 43():199-223. PubMed ID: 37207355
[TBL] [Abstract][Full Text] [Related]
20. Omega-3 polyunsaturated fatty acids in the treatment of non-alcoholic fatty liver disease: An umbrella systematic review and meta-analysis.
Musazadeh V; Karimi A; Malekahmadi M; Ahrabi SS; Dehghan P
Clin Exp Pharmacol Physiol; 2023 May; 50(5):327-334. PubMed ID: 36692292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
